Pre-therapeutic 124I PET(/CT) dosimetry confirms low average absorbed doses per administered 131I activity to the salivary glands in radioiodine therapy of differentiated thyroid cancer
1. Klinik für Nuklearmedizin, Universit?t Duisburg-Essen, Hufelandstrasse 55, 45122, Essen, Germany 2. Department of Radiology, School of Medicine, Johns Hopkins University, Baltimore, MD, USA
Abstract:
Purpose
Salivary gland impairment following high activity radioiodine therapy of differentiated thyroid cancer (DTC) is a severe side
effect. Dosimetric calculations using planar gamma camera scintigraphy (GCS) with 131I and ultrasonography (US) provided evidence that the average organ dose per administered 131I activity (ODpA) is too low to account for observed radiation damages to the salivary glands. The objective of this work
was to re-estimate the ODpA using 124I PET(/CT) as a more reliable approach than 131I GCS/US.